Shuang Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuang Hu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Xi Li
National Clinical Research Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
4 shared publications - Xin Zheng
National Clinical Research Center for Cardiovascular Diseases, NHC Key Laboratory of Clinical Research for Cardiovascular Medications, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing, China
4 shared publications - Harlan M. Krumholz
Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
3 shared publications - Jing Li
National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 shared publications - Bin Wang
Chinese Academy of Medical Sciences and Peking Union Medical College, National Center for Cardiovascular Diseases
2 shared publications - Erica Sarah Spatz
Yale School of Medicine
2 shared publications
Latest Publications
- Open Access
- 1 June 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 15 (6) , 405-415
Sex Differences in Characteristics, Treatments, and Outcomes Among Patients Hospitalized for Non–ST-Segment–Elevation Myocardial Infarction in China: 2006 to 2015
Background: Sex differences in clinical characteristics and in-hospital outcomes among patients with non–ST-segment–elevation myocardial infarction have been described in Western countries, but whether these differences exist in China is unknown. Methods: We used a 2-stage random sampling design to create a nationally representative sample of patients admitted to 151 Chinese hospitals for non–ST-segment–elevation myocardial infarction in 2006, 2011, and 2015 and examined sex differences in clinical profiles, treatments, and in-hospital outcomes over this time. Multivariable logistic regression models adjusting for age or other potentially confounding clinical covariates were used to estimate these sex-specific differences. Results: Among 4611 patients, the proportion of women (39.8%) was unchanged between 2006 and 2015. Women were older with higher rates of hypertension, diabetes, and dyslipidemia. Among patients without contraindications, women were less likely to receive treatments than men, with significant differences for aspirin in 2015 (90.3% versus 93.9%) and for invasive strategy in 2011 (28.7% versus 45.7%) and 2015 (34.0% versus 48.4%). After adjusting for age, such differences in aspirin and invasive strategy in 2015 were not significant, but the difference in invasive strategy in 2011 persisted. The sex gaps in the use of invasive strategy did not narrow. From 2006 to 2015, a significant decrease in in-hospital mortality was observed in men (from 16.9% to 8.7%), but not in women (from 11.8% to 12.0%), with significant interaction between sex and study year (P=0.023). After adjustment, in-hospital mortality in women was significantly lower than men in 2006, but not in 2011 or 2015. Conclusions: Sex differences in cardiovascular risk factors and invasive strategy after non–ST-segment–elevation myocardial infarction were observed between 2011 and 2015 in China. Although sex gaps in in-hospital mortality were largely explained by age differences, efforts to narrow sex-related disparities in quality of care should remain a focus. Registration: URL: http://www.clinicaltrials.gov; Unique identifier: NCT01624883.
- 1 June 2022
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 15 (6) , 405-415
Open AccessSex Differences in Characteristics, Treatments, and Outcomes Among Patients Hospitalized for Non–ST-Segment–Elevation Myocardial Infarction in China: 2006 to 2015
Background: Sex differences in clinical characteristics and in-hospital outcomes among patients with non–ST-segment–elevation myocardial infarction have been described in Western countries, but whether these differences exist in China is unknown. Methods: We used a 2-stage random sampling design to create a nationally representative sample of patients admitted to 151 Chinese hospitals for non–ST-segment–elevation myocardial infarction in 2006, 2011, and 2015 and examined sex differences in clinical profiles, treatments, and in-hospital outcomes over this time. Multivariable logistic regression models adjusting for age or other potentially confounding clinical covariates were used to estimate these sex-specific differences. Results: Among 4611 patients, the proportion of women (39.8%) was unchanged between 2006 and 2015. Women were older with higher rates of hypertension, diabetes, and dyslipidemia. Among patients without contraindications, women were less likely to receive treatments than men, with significant differences for aspirin in 2015 (90.3% versus 93.9%) and for invasive strategy in 2011 (28.7% versus 45.7%) and 2015 (34.0% versus 48.4%). After adjusting for age, such differences in aspirin and invasive strategy in 2015 were not significant, but the difference in invasive strategy in 2011 persisted. The sex gaps in the use of invasive strategy did not narrow. From 2006 to 2015, a significant decrease in in-hospital mortality was observed in men (from 16.9% to 8.7%), but not in women (from 11.8% to 12.0%), with significant interaction between sex and study year (P=0.023). After adjustment, in-hospital mortality in women was significantly lower than men in 2006, but not in 2011 or 2015. Conclusions: Sex differences in cardiovascular risk factors and invasive strategy after non–ST-segment–elevation myocardial infarction were observed between 2011 and 2015 in China. Although sex gaps in in-hospital mortality were largely explained by age differences, efforts to narrow sex-related disparities in quality of care should remain a focus. Registration: URL: http://www.clinicaltrials.gov; Unique identifier: NCT01624883.
- 1 January 2022
- Published by Elsevier in Statistics & Probability Letters
- Vol. 180, 109235
Tail dependence functions of the bivariate Hüsler–Reiss model
- 1 January 2022
- Published by Elsevier in Statistics & Probability Letters
- Vol. 180, 109235
Tail dependence functions of the bivariate Hüsler–Reiss model
- Open Access
- 1 April 2021
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 39 (Supplement) , e83
BLOOD PRESSURE AT ADMISSION PREDICTS 1-YEAR OUTCOMES OF PATIENTS HOSPITALIZED FOR HEART FAILURE
Objective: This study aimed to evaluate the association between admission blood pressure (BP) and 1-year clinical outcomes in patients hospitalized for heart failure (HF) stratified by left ventricular ejection fraction (LVEF). Design and method: In the China PEACE Prospective Heart Failure Study, 4,930 patients hospitalized primarily for HF in 52 hospitals from 20 provinces in China have been enrolled. We included 4,611 patients with available LVEF and admission BP into analysis. Heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) were defined as LVEF < 40%, LVEF of 40–49%, and LVEF > = 50%, respectively. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at admission were categorized by 10 mmHg increments. The primary outcome was the composite of all-cause death or HF readmission within 1 year after admission. The association between BP and the outcome was estimated with Cox proportional hazard models. A generalized additive model with restricted cubic splines was used to explore the possible non-linear relationship between BP and the outcome. Results: In our study, there were 1,850 (40.1%), 1035 (22.4%) and 1,726 (37.4%) patients with HFrEF, HFmrEF and HFpEF, respectively. In the multivariable analysis, compared to SBP of 120–129 mmHg, SBP > = 150 mmHg was significantly associated with a lower risk in HFrEF and SBP < 110 mmHg was significantly associated with a higher risk in HFmrEF and HFpEF (Table 1). For DBP, a significant decrease in the risk was observed for DBP > = 100 mmHg and DBP of 90–99 mmHg compared with DBP of 70–79 mmHg in HFrEF and HFpEF, respectively (Table 1). SBP and DBP were inversely and linearly associated with the primary outcome in HFrEF and HFpEF. Conversely, in HFmrEF, the association between SBP or DBP with the primary outcome was nonlinear. Conclusions: In patients hospitalized for HF, different prognostic effects of admission BP on clinical outcomes have been found by LVEF status. In HFrEF and HFpEF, the risk of clinical outcomes increased significantly only at lower BP, however, in HFmrEF, there is a nonlinear trend between BP and clinical outcomes.
- 1 April 2021
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 39 (Supplement) , e83
Open AccessBLOOD PRESSURE AT ADMISSION PREDICTS 1-YEAR OUTCOMES OF PATIENTS HOSPITALIZED FOR HEART FAILURE
Objective: This study aimed to evaluate the association between admission blood pressure (BP) and 1-year clinical outcomes in patients hospitalized for heart failure (HF) stratified by left ventricular ejection fraction (LVEF). Design and method: In the China PEACE Prospective Heart Failure Study, 4,930 patients hospitalized primarily for HF in 52 hospitals from 20 provinces in China have been enrolled. We included 4,611 patients with available LVEF and admission BP into analysis. Heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF), and heart failure with preserved ejection fraction (HFpEF) were defined as LVEF < 40%, LVEF of 40–49%, and LVEF > = 50%, respectively. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at admission were categorized by 10 mmHg increments. The primary outcome was the composite of all-cause death or HF readmission within 1 year after admission. The association between BP and the outcome was estimated with Cox proportional hazard models. A generalized additive model with restricted cubic splines was used to explore the possible non-linear relationship between BP and the outcome. Results: In our study, there were 1,850 (40.1%), 1035 (22.4%) and 1,726 (37.4%) patients with HFrEF, HFmrEF and HFpEF, respectively. In the multivariable analysis, compared to SBP of 120–129 mmHg, SBP > = 150 mmHg was significantly associated with a lower risk in HFrEF and SBP < 110 mmHg was significantly associated with a higher risk in HFmrEF and HFpEF (Table 1). For DBP, a significant decrease in the risk was observed for DBP > = 100 mmHg and DBP of 90–99 mmHg compared with DBP of 70–79 mmHg in HFrEF and HFpEF, respectively (Table 1). SBP and DBP were inversely and linearly associated with the primary outcome in HFrEF and HFpEF. Conversely, in HFmrEF, the association between SBP or DBP with the primary outcome was nonlinear. Conclusions: In patients hospitalized for HF, different prognostic effects of admission BP on clinical outcomes have been found by LVEF status. In HFrEF and HFpEF, the risk of clinical outcomes increased significantly only at lower BP, however, in HFmrEF, there is a nonlinear trend between BP and clinical outcomes.
- Open Access
- 27 March 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 8 (2) , 140-148
β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction
Aims: The beneficial effect of β-blocker on heart failure with reduced ejection fraction is well established. However, its effect on the 1-year outcome of heart failure with mid-range ejection fraction (HFmrEF) remains unclear. Methods and results: We analysed the data of the patients with left ventricular ejection fraction (LVEF) between 40% and 49% in China Patient-centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study (China PEACE 5p-HF Study), in which patients hospitalized for heart failure from 52 Chinese hospitals were recruited from 2016 to 2018. Two primary outcomes were all-cause death and all-cause hospitalization. The associations between β-blocker use at discharge and outcomes were assessed by inverse probability of treatment weighting (IPTW)-weighted Cox regression analyses. To assess consistency, IPTW adjusting medications analyses, multivariable analyses and dose-effect analyses were performed. A total of 1035 HFmrEF patients were included in the analysis. The mean age was 65.5 ± 12.7 years and 377 (36.4%) were female. The median (interquartile range) of LVEF was 44% (42–47%). Six hundred and sixty-one (63.8%) were treated with β-blocker. Patients using β-blocker were younger with better cardiac function, and more likely to use renin–angiotensin system inhibitor and mineralocorticoid receptor antagonist. During the 1-year follow-up, death occurred in 84 (12.7%) treated and 85 (22.7%) untreated patients (P < 0.0001); all-cause hospitalization occurred in 298 (45.1%) treated and 188 (50.3%) untreated patients (P = 0.04). After IPTW-weighted adjustment, β-blocker use was significantly associated with lower risk of all-cause death [hazard ratio (HR): 0.70; 95% confidence interval (CI): 0.51–0.96, P = 0.03], but not with lower all-cause hospitalization (HR, 0.92, 95% CI, 0.76–1.10, P = 0.36). Consistency analyses showed consistent favourable effect of β-blocker on all-cause death, but not on all-cause hospitalization. Conclusions: Among patients with HFmrEF, β-blocker use was associated with lower risk of all-cause death, but not with lower risk of all-cause hospitalization.
- 27 March 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 8 (2) , 140-148
Open Accessβ-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction
Aims: The beneficial effect of β-blocker on heart failure with reduced ejection fraction is well established. However, its effect on the 1-year outcome of heart failure with mid-range ejection fraction (HFmrEF) remains unclear. Methods and results: We analysed the data of the patients with left ventricular ejection fraction (LVEF) between 40% and 49% in China Patient-centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study (China PEACE 5p-HF Study), in which patients hospitalized for heart failure from 52 Chinese hospitals were recruited from 2016 to 2018. Two primary outcomes were all-cause death and all-cause hospitalization. The associations between β-blocker use at discharge and outcomes were assessed by inverse probability of treatment weighting (IPTW)-weighted Cox regression analyses. To assess consistency, IPTW adjusting medications analyses, multivariable analyses and dose-effect analyses were performed. A total of 1035 HFmrEF patients were included in the analysis. The mean age was 65.5 ± 12.7 years and 377 (36.4%) were female. The median (interquartile range) of LVEF was 44% (42–47%). Six hundred and sixty-one (63.8%) were treated with β-blocker. Patients using β-blocker were younger with better cardiac function, and more likely to use renin–angiotensin system inhibitor and mineralocorticoid receptor antagonist. During the 1-year follow-up, death occurred in 84 (12.7%) treated and 85 (22.7%) untreated patients (P < 0.0001); all-cause hospitalization occurred in 298 (45.1%) treated and 188 (50.3%) untreated patients (P = 0.04). After IPTW-weighted adjustment, β-blocker use was significantly associated with lower risk of all-cause death [hazard ratio (HR): 0.70; 95% confidence interval (CI): 0.51–0.96, P = 0.03], but not with lower all-cause hospitalization (HR, 0.92, 95% CI, 0.76–1.10, P = 0.36). Consistency analyses showed consistent favourable effect of β-blocker on all-cause death, but not on all-cause hospitalization. Conclusions: Among patients with HFmrEF, β-blocker use was associated with lower risk of all-cause death, but not with lower risk of all-cause hospitalization.
- Open Access
- 22 February 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (2) , 1438-1445
Use of Angiotensin Receptor Blocker is Associated with Improved 1 Year Mortality in Heart Failure with Mid-Range Ejection Fraction
Aims Current evidence about the effect of angiotensin receptor blocker (ARB) on the outcome of heart failure with mid‐range ejection fraction (HFmrEF) is lacking. We aim to assess the association between use of ARB and 1 year all‐cause mortality after hospitalization for HFmrEF. Methods and results We analysed the data of patients with ejection fraction of 40–49% in China Patient‐centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study; 4907 patients hospitalized for heart failure from 52 Chinese hospitals were enrolled from August 2016 to May 2018. Use of ARB was determined by prescriptions at discharge. Patients who died during hospitalization or were using angiotensin‐converting enzyme inhibitors at discharge were excluded. The association between the use of ARB and outcome was assessed using stabilized inverse probability of treatment weighting‐adjusted Kaplan–Meier and Cox regression analyses. A total of 701 patients with HFmrEF were included for analysis. The mean age was 66.4 ± 12.8 years, and 267 (38.1%) were female. Of them, 244 were treated (34.8%) with ARB. During the 1 year follow‐up period, patients treated with ARB had lower all‐cause mortality compared with untreated patients (11.5% vs. 21.9%, P = 0.0005). Inverse probability of treatment weighting‐adjusted Cox regression analysis showed that use of ARB was associated with significantly reduced all‐cause mortality (adjusted hazard ratio 0.44, 95% confidence interval 0.28–0.69, P = 0.0004). Conclusions Among patients hospitalized for HFmrEF, the use of ARB was associated with lower 1 year mortality after discharge.
- 22 February 2021
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 8 (2) , 1438-1445
Open AccessUse of Angiotensin Receptor Blocker is Associated with Improved 1 Year Mortality in Heart Failure with Mid-Range Ejection Fraction
Aims Current evidence about the effect of angiotensin receptor blocker (ARB) on the outcome of heart failure with mid‐range ejection fraction (HFmrEF) is lacking. We aim to assess the association between use of ARB and 1 year all‐cause mortality after hospitalization for HFmrEF. Methods and results We analysed the data of patients with ejection fraction of 40–49% in China Patient‐centred Evaluative Assessment of Cardiac Events Prospective Heart Failure Study; 4907 patients hospitalized for heart failure from 52 Chinese hospitals were enrolled from August 2016 to May 2018. Use of ARB was determined by prescriptions at discharge. Patients who died during hospitalization or were using angiotensin‐converting enzyme inhibitors at discharge were excluded. The association between the use of ARB and outcome was assessed using stabilized inverse probability of treatment weighting‐adjusted Kaplan–Meier and Cox regression analyses. A total of 701 patients with HFmrEF were included for analysis. The mean age was 66.4 ± 12.8 years, and 267 (38.1%) were female. Of them, 244 were treated (34.8%) with ARB. During the 1 year follow‐up period, patients treated with ARB had lower all‐cause mortality compared with untreated patients (11.5% vs. 21.9%, P = 0.0005). Inverse probability of treatment weighting‐adjusted Cox regression analysis showed that use of ARB was associated with significantly reduced all‐cause mortality (adjusted hazard ratio 0.44, 95% confidence interval 0.28–0.69, P = 0.0004). Conclusions Among patients hospitalized for HFmrEF, the use of ARB was associated with lower 1 year mortality after discharge.
- Open Access
- 11 April 2019
- Published by Springer Nature in BMC Geriatrics
- Vol. 19 (1) , 103
Persistent geographic variations in availability and quality of nursing home care in the United States: 1996 to 2016
Availability of nursing home care has declined and national efforts have been initiated to improve the quality of nursing home care in the U.S. Yet, data are limited on whether there are geographic variations in declines of availability and quality of nursing home care, and whether variations persist over time. We sought to assess geographic variation in availability and quality of nursing home care. Retrospective study using Medicaid/Medicare-certified nursing home data from the Centers for Medicare & Medicaid Services, 1996–2016. Outcomes were 1) availability of all nursing home care (1996–2016), measured by the number of Medicaid/Medicare-certified beds for a given county per 100,000 population aged ≥65 years, regardless of nursing home star rating; 2) availability of 5-star nursing home care, measured by the number of Medicaid/Medicare-certified beds provided by 5-star nursing homes; and 3) utilization of nursing home beds, defined as the rate of occupied Medicaid/Medicare-certified beds among the total Medicaid/Medicare-certified beds. From 1999 to 2016, availability of all nursing home care declined from 4882 (standard deviation: 931) to 3480 (912) beds, per 100,000 population aged ≥65 years. Persistent geographic variation in availability of nursing home care was observed; the correlation coefficient of county-specific availabilities from 1996 to 2016 was 0.78 (95% CI 0.77–0.79). From 2011 to 2016, availability of 5-star nursing home beds increased from 658 (303) to 895 (661) per 100,000 population aged ≥65 years. The correlation coefficient for county-specific availabilities from 2011 to 2016 was 0.54 (95% CI 0.51–0.56). Availability and quality of nursing home care were not highly correlated. In 2016, the correlation coefficient for county-specific availabilities between all nursing home and 5-star nursing home beds was 0.33 (95% CI 0.30–0.36). From 1996 to 2016, the utilization of certified beds declined from 78.5 to 72.2%. This decline was consistent across all census divisions, but most pronounced in the Mountain division and less in the South-Atlantic division. We observed persistent geographic variations in availability and quality of nursing home care. Availability of all nursing home care declined but availability of 5-star nursing home care increased. Availability and quality of nursing home care were not highly correlated.
- 11 April 2019
- Published by Springer Nature in BMC Geriatrics
- Vol. 19 (1) , 103
Open AccessPersistent geographic variations in availability and quality of nursing home care in the United States: 1996 to 2016
Availability of nursing home care has declined and national efforts have been initiated to improve the quality of nursing home care in the U.S. Yet, data are limited on whether there are geographic variations in declines of availability and quality of nursing home care, and whether variations persist over time. We sought to assess geographic variation in availability and quality of nursing home care. Retrospective study using Medicaid/Medicare-certified nursing home data from the Centers for Medicare & Medicaid Services, 1996–2016. Outcomes were 1) availability of all nursing home care (1996–2016), measured by the number of Medicaid/Medicare-certified beds for a given county per 100,000 population aged ≥65 years, regardless of nursing home star rating; 2) availability of 5-star nursing home care, measured by the number of Medicaid/Medicare-certified beds provided by 5-star nursing homes; and 3) utilization of nursing home beds, defined as the rate of occupied Medicaid/Medicare-certified beds among the total Medicaid/Medicare-certified beds. From 1999 to 2016, availability of all nursing home care declined from 4882 (standard deviation: 931) to 3480 (912) beds, per 100,000 population aged ≥65 years. Persistent geographic variation in availability of nursing home care was observed; the correlation coefficient of county-specific availabilities from 1996 to 2016 was 0.78 (95% CI 0.77–0.79). From 2011 to 2016, availability of 5-star nursing home beds increased from 658 (303) to 895 (661) per 100,000 population aged ≥65 years. The correlation coefficient for county-specific availabilities from 2011 to 2016 was 0.54 (95% CI 0.51–0.56). Availability and quality of nursing home care were not highly correlated. In 2016, the correlation coefficient for county-specific availabilities between all nursing home and 5-star nursing home beds was 0.33 (95% CI 0.30–0.36). From 1996 to 2016, the utilization of certified beds declined from 78.5 to 72.2%. This decline was consistent across all census divisions, but most pronounced in the Mountain division and less in the South-Atlantic division. We observed persistent geographic variations in availability and quality of nursing home care. Availability of all nursing home care declined but availability of 5-star nursing home care increased. Availability and quality of nursing home care were not highly correlated.
- 1 May 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 8 (suppl_2)
Abstract 161: National Trends in Use of Radial Access for Percutaneous Coronary Intervention in China: 2001-2011
Background: The use of radial access for percutaneous coronary intervention (r-PCI) is associated with reduced risk of bleeding complications and higher patient satisfaction. However, the use of r-PCI differs greatly by country and is unknown in China. We examined trends in the adoption of r-PCI in China over the past decade and identified factors associated with its use. Methods: We used a two-stage random sampling strategy to create a nationally representative sample of 5,462 patients undergoing percutaneous coronary intervention (PCI) in China in 2001 (n=402; 24 sites), 2006 (n=1,390; 44 sites), and 2011 (n=3,670; 54 sites). We calculated the weighted proportion of patients receiving r-PCI in each time period and conducted multivariable analysis to identify the patient and hospital characteristics associated with not receiving r-PCI in 2011. Results: Among 5,462 patients who underwent PCI, the use of r-PCI increased markedly over time (2001: 3.4% [95% CI 0.0%-8.5%]; 2006: 36.5% [95% CI 34.2%-38.9%], 2011: 74.7% [95% CI 73.9-75.6]; P for trend Conclusion: Over a recent ten-year period, radial access became the predominant strategy for PCI in China, even among high-risk patients. This study demonstrates the responsiveness of the interventional cardiology community to emerging evidence. A deeper understanding of the factors facilitating r-PCI adoption in China may help increase its usage in countries in which r-PCI use remains low. Download figure
- 1 May 2015
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 8 (suppl_2)
Abstract 161: National Trends in Use of Radial Access for Percutaneous Coronary Intervention in China: 2001-2011
Background: The use of radial access for percutaneous coronary intervention (r-PCI) is associated with reduced risk of bleeding complications and higher patient satisfaction. However, the use of r-PCI differs greatly by country and is unknown in China. We examined trends in the adoption of r-PCI in China over the past decade and identified factors associated with its use. Methods: We used a two-stage random sampling strategy to create a nationally representative sample of 5,462 patients undergoing percutaneous coronary intervention (PCI) in China in 2001 (n=402; 24 sites), 2006 (n=1,390; 44 sites), and 2011 (n=3,670; 54 sites). We calculated the weighted proportion of patients receiving r-PCI in each time period and conducted multivariable analysis to identify the patient and hospital characteristics associated with not receiving r-PCI in 2011. Results: Among 5,462 patients who underwent PCI, the use of r-PCI increased markedly over time (2001: 3.4% [95% CI 0.0%-8.5%]; 2006: 36.5% [95% CI 34.2%-38.9%], 2011: 74.7% [95% CI 73.9-75.6]; P for trend Conclusion: Over a recent ten-year period, radial access became the predominant strategy for PCI in China, even among high-risk patients. This study demonstrates the responsiveness of the interventional cardiology community to emerging evidence. A deeper understanding of the factors facilitating r-PCI adoption in China may help increase its usage in countries in which r-PCI use remains low. Download figure